Document is current
Any future updates will be listed below
-
Authors
,
Pagani, Silvia https://orcid.org/0000-0002-1493-2269
Lombardi, Niccolò https://orcid.org/0000-0002-9666-0438
Crescioli, Giada https://orcid.org/0000-0002-1071-6120
Vighi, Giuditta Violetta https://orcid.org/0000-0001-5771-124X
Spada, Giulia https://orcid.org/0000-0002-1254-7500
Romoli, Isabella https://orcid.org/0000-0001-9788-6490
Andreetta, Paola https://orcid.org/0000-0002-1851-3141
Capuano, Annalisa https://orcid.org/0000-0002-8653-2408
Marrazzo, Eleonora https://orcid.org/0000-0003-4832-3485
Marra, Anna https://orcid.org/0000-0003-1163-4263
Leoni, Olivia https://orcid.org/0000-0002-6906-2424
Vannacci, Alfredo https://orcid.org/0000-0001-5259-2026
Venegoni, Mauro https://orcid.org/0000-0002-5462-5327
Vighi, Giuseppe Danilo https://orcid.org/0000-0001-6008-7177
-
Funding
Funding for this research was provided by:
Fondi Regionali per la Farmacovigilanza
- License Information
-
More Information
Article History
Received: 3 April 2020
Accepted: 28 September 2020
First Online: 4 January 2021
Compliance with ethical standards
:
: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
: The MEREAFaPS Study was approved in 2006 by the local institutional ethics committee of the coordinating centre, Niguarda Ca’ Granda Hospital, according to the legal requirements concerning observational studies [].
: Due to the retrospective nature of the present study and data anonymization, patient’s consent to participate was not required.
